Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine functions by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if administered later in the third trimester.

• Nearly 85 per cent protection when vaccinated 4 weeks before birth
• Maternal antibodies transferred through the placenta safeguard newborns from day one
• Protection achievable with two-week gap before premature birth
• Vaccination during the third trimester still offers significant infant protection

Compelling evidence from the latest research

The efficacy of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study undertaken in England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s actual performance. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scope of this study offers healthcare professionals and expectant parents with assurance in the vaccine’s established performance across diverse populations and circumstances.

The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This marked difference underscores the vaccine’s critical role in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and the dangers

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it perilously hard for infected babies to breathe and feed effectively. Parents commonly see their babies fighting for breath, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies get better with clinical support, a limited though important number die from respiratory syncytial virus complications each year, making immunisation programmes a critical public health objective for safeguarding the youngest and most vulnerable individuals in the population.

• RSV produces lung inflammation, resulting in severe breathing difficulties in infants
• Half of all infants contract the infection during their first few months alive
• Symptoms range from mild colds to serious chest infections that threaten life needing hospital treatment
• More than 20,000 UK babies need serious hospital treatment for RSV each year
• Small numbers of babies die from RSV related complications annually in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies through the placenta.

The communication from public health bodies stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.

Regional differences in vaccination

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations demonstrate variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts launching varied communication campaigns to connect with expectant mothers
• Inconsistencies across regions in vaccination coverage levels throughout England demand focused enhancement
• Local healthcare systems modifying schemes to align with local requirements and situations

Real-world impact and parental perspectives

The vaccine’s outstanding effectiveness provides tangible benefits for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this protective measure, the 80% reduction in admissions represents thousands of infants protected against severe infection. Parents no more face the distressing scenario of seeing their babies gasping for air or labour to feed, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the landscape of neonatal respiratory health, giving expectant mothers a preventative option to safeguard their youngest infants during those critical early months.

For families like that of Malachi, whose acute RSV infection caused severe brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s support of the jab emphasises the profound consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women during their third trimester, converting what was once an inevitable seasonal threat into a manageable health risk.